Zelmac

Quick links to important sections

Zelmac

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zelmac

What is Zelmac?

Zelmac is a pharmaceutical medication containing the active substance tegaserod. It belongs to a class of drugs known as serotonin receptor agonists, specifically targeting 5-HT4 receptors located in the gastrointestinal tract.

Mechanism of Action

The medication works by mimicking the effects of serotonin, a naturally occurring chemical in the body that regulates intestinal movement. By stimulating the 5-HT4 receptors, the medication helps to:

  • Increase the speed of movement of food and waste through the stomach and intestines.
  • Trigger the secretion of fluids into the intestines.
  • Modulate visceral sensitivity, which can influence how the body perceives abdominal discomfort.

Primary Uses

Zelmac is primarily utilized for the management of specific functional gastrointestinal disorders. Its development focused on addressing conditions characterized by reduced motility and abdominal symptoms.

Irritable Bowel Syndrome with Constipation (IBS-C)

In patients with IBS-C, the medication is used to alleviate symptoms such as infrequent bowel movements, abdominal pain, and bloating. It is generally intended for short-term, intermittent treatment.

Chronic Idiopathic Constipation

The medication is also used for individuals experiencing chronic constipation that does not have a known underlying physical cause (idiopathic). It helps facilitate more regular bowel activity by enhancing the natural contractions of the digestive system.

Regulatory References

  1. DrugBank Online
  2. Irritable Bowel Syndrome with Constipation (IBS-C)

What side effects are possible with Zelmac?

The official safety documentation for tegaserod maleate (Zelmac) establishes specific adverse reaction categories, with the most frequent effects being related to the gastrointestinal system.

General Adverse Reactions

Side effects commonly reported in clinical trials include Headache and Diarrhea (classified as Most Common in regulatory documents). Other common gastrointestinal reactions listed are Abdominal pain, Nausea, Flatulence, Dyspepsia, and Dizziness. Diarrhea, while common, has been reported in post-marketing experience to have serious consequences, including Hypovolemia, Hypotension, and Syncope.

Serious Adverse Reactions and Safety Constraints

The safety profile is characterized by the risk of Serious Adverse Cardiovascular Events (MACE), including documented reports of Myocardial Infarction, Stroke, and Transient Ischemic Attack. Additionally, a serious gastrointestinal risk is Ischemic Colitis, which has been reported post-marketing. The label also notes reports of Suicidal Ideation and Behavior in clinical trials, with monitoring required during the initial treatment months.

Population and Disease Restrictions

Use is officially restricted to adult women under 65 years of age and is subject to strict contraindications defined in the regulatory labeling. The medication must not be used in individuals with a history of any major cardiovascular ischemic event, Ischemic Colitis, Bowel Obstruction, or symptomatic Gallbladder Disease. It is also contraindicated in patients with severe renal impairment or moderate or severe hepatic impairment.

Overdose and Emergency Response

Zelmac overdose information is derived from documented cases, including exposures up to twenty times the recommended therapeutic dose. Officially documented clinical manifestations primarily involve an escalation of the drug's gastrointestinal effects. These overdose presentations include severe diarrhea, abdominal pain, flatulence, nausea, vomiting, and headache, with some instances noting orthostatic hypotension.

The most serious outcomes are associated with the risk of fluid loss. Severe diarrhea may lead to hypovolemia (volume depletion), which can escalate to hypotension (low blood pressure) and syncope (fainting), as detailed in official prescribing information.

Regulatory guidance mandates that patients or caregivers seek immediate medical attention and contact emergency services for a suspected overdose. The medication must be discontinued immediately if severe symptoms such as syncope or severe hypotension occur. Management of Zelmac overdose is limited to symptomatic and supportive treatment, as no specific antidote is listed in the regulatory labeling. Hospitalization for rehydration may be required to correct severe fluid and electrolyte imbalances resulting from volume depletion.

Therapeutic Uses of Zelmac

What Zelmac Treats: Main Uses and Benefits

This medication is primarily used to help manage the recurrent and episodic symptoms of Irritable Bowel Syndrome with Constipation (IBS-C) in adult women under the age of 65. It is applied across domains where additional symptomatic support is needed.


The therapy is relevant for easing symptoms related to physical discomfort that often cluster together, and is applied in addressing symptoms such as abdominal pain and cramping, infrequent and difficult passage of stools, and bloating or abdominal distension. It is commonly used when symptoms create noticeable interference with daily functioning, offering supportive management across this key diagnostic domain.

This focus on symptomatic relief supports patients during episodes of heightened discomfort and assists with maintaining functional stability.

Quick Fact: Relief for Straining and Infrequent Stools This medication is commonly used to help manage the difficulty and straining associated with infrequent bowel movements, which are key symptoms linked to organ-specific functional stress in IBS-C.

Regulatory References

  1. NIH DailyMed Prescribing Information

Eligibility and Restrictions for Use

Zelmac (tegaserod) use is strictly limited by regulatory authorities to adult women under 65 years of age with Irritable Bowel Syndrome with Constipation (IBS-C).


Absolute Contraindications

The medicine is contraindicated and must not be used in several populations due to specific health risks. This includes individuals with a history of Major Adverse Cardiovascular Events (MACE) such as heart attack, stroke, or angina. It is also prohibited for patients with a history of ischemic colitis, other forms of intestinal ischemia, or pre-existing conditions like bowel obstruction, symptomatic gallbladder disease, or abdominal adhesions.

Organ Function and Special Populations

Eligibility is also defined by organ function; the drug is contraindicated in cases of moderate or severe hepatic impairment and severe renal impairment. Use is officially not established or not indicated for men, the pediatric population, and women 65 years of age or older. Furthermore, the label advises that breastfeeding is not recommended during treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for tegaserod maleate (Zelmac) is defined by pharmacokinetic considerations, including drug-food interactions and restrictions based on patient-specific clearance capacity.

Documented Pharmacokinetic Interaction Patterns

Co-administration with a meal results in a significant drug-food interaction. Taking the medication with food reduces the overall bioavailability of tegaserod by 40% to 65% and lowers the peak plasma concentration ( C max). Similar reductions occur if the medicine is taken too close to a meal (within 30 minutes before or 2.5 hours after), necessitating separation from food to maximize systemic exposure.

Conversely, clinical studies have documented a lack of clinically relevant drug-drug interactions with several common medications. Tegaserod does not significantly alter the pharmacokinetics of the P-glycoprotein substrate digoxin or the CYP substrates warfarin and oral contraceptives containing ethinyl estradiol. It also showed no clinically relevant interaction with probe substrates for CYP1A2 or CYP2D6 (theophylline and dextromethorphan).

Population-Dependent Restrictions

Use of Zelmac is formally contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh B or C) and in those with severe renal impairment or end-stage renal disease. This restriction is based on altered drug or metabolite exposure in these populations. Patients with mild hepatic impairment (Child-Pugh A) also show increased systemic exposure (AUC and C max) compared to those with normal function.

Mechanism of Action

5-HT4 Receptor Partial Agonism

The active ingredient, tegaserod maleate, functions as a partial agonist for the Serotonin-4 mathbf(5-HT4) receptors located on enteric neurons and epithelial cells in the intestinal wall. This targeted interaction initiates the subsequent signaling events that determine the drug's physiological effects.


Enhancement of Propulsive Motility

Stimulation of the 5-HT4 receptors on enteric neurons facilitates the release of excitatory neurotransmitters like Acetylcholine (ACh). This chemical signal strengthens and accelerates the peristaltic reflex—the coordinated muscle contractions necessary for gut propulsion—which accelerates the transit rate of luminal contents.


Secretion and Sensory Modulation

Beyond motility, the mechanism involves dual action. Activation of 5-HT4 receptors on enterocytes promotes the secretion of fluid and ions into the intestinal lumen, which results in the increased water and ion content of luminal contents. Simultaneously, the drug's overall influence on the gut's sensory pathways results in a down-modulation of afferent visceral input.

Dosage and Administration Information

How to Use Zelmac — Administration Guidelines

Zelmac (tegaserod) usage is defined by guidelines outlining the required administration pattern and population constraints. The medication is supplied as an immediate-release oral tablet.


Administration Scope

Instruction Detail
Route of administration Oral (by mouth).
Dosing schedule (official regimen) 6 mg twice daily (b.i.d.).
Timing in relation to meals Must be administered at least 30 minutes before a meal to ensure proper absorption.
Age-group administration rules Not used in women 65 years of age or older. Safety and efficacy are not established in pediatric patients.
Missed-dose rules If a scheduled dose is missed, the patient is instructed to skip that dose and resume the standard schedule at the next designated time.
Course duration The initial treatment course is defined as 4 to 6 weeks. Discontinuation is specified if adequate symptom control has not been achieved within this period.

Instruction Classifications

Classification Detail
Administration method type Oral, short-acting tablet.
Frequency pattern Twice daily (b.i.d.) administration in a time-limited course.
Use-context constraints Administration is subject to strict timing requirements relative to food intake and is limited by age and patient organ function status (e.g., severe hepatic or renal impairment).

Connection to the Overall Use Protocol

The official use protocol is structured around a fixed, short-term treatment course involving 6 mg twice daily, which is linked to food timing for optimal systemic exposure. This standardized approach is confined to a specific patient population, with clear instructions provided for dose timing and continuation of the initial course.

Recent Clinical Evidence

Research Evidence for Zelmac (Tegaserod)


Evidence for use in Irritable Bowel Syndrome with Constipation (IBS-C)

The primary body of evidence for Zelmac comes from short-term (12-week) Randomized Controlled Trials (RCTs), which are a research standard used to evaluate medicines. These studies were used in research exploring how symptoms change over time in patients with Irritable Bowel Syndrome with Constipation (IBS-C). The research examined primarily adult women diagnosed with IBS-C, as this has been the main population of focus for regulatory evaluation.

The main studies monitored patient-reported outcomes describing perceived discomfort, such as the symptom changes reported as overall relief of IBS symptoms. Studies conducted during periods of increased symptom activity reported patterns related to overall symptom relief compared to the placebo groups in the short term. Research describes changes measured during the study period for outcomes related to physical discomfort and bowel movements. These findings describe patterns observed in the studies and contribute to the broader evidence landscape related to IBS-C management.


Studies on Long-Term and Intermittent Use

Most pivotal placebo-controlled trials were designed to observe responses over defined time intervals of about 12 weeks. For long-term understanding, patients who were observed to respond to initial short-term treatment were sometimes observed in open-label extension studies, where long-term effects are not fully established.

Trials were also conducted to specifically assess the feasibility of repeated treatment cycles. Research examined how patients who previously were observed to respond fared when they received treatment again after a symptom-free interval. These studies described patterns of symptomatic response during retreatment, and research examined its use in contexts involving episodic or acute changes in IBS-C symptoms.


What is Still Uncertain About the Research

One key gap is the limited information for long-term outcomes and the persistence of any patterns observed over many months or years, as most rigorous studies were short-term. The research relies heavily on patient-reported outcomes, which means findings help contextualize how patients reported their experience.

Furthermore, because the trials focused on a highly selected group—adult women without certain risk factors—the results apply only to the populations studied, and the existing studies provide limited insight into how the general population of IBS-C patients, or subgroups like men, might be observed to respond. Comparative evidence against other current IBS-C therapies is also lacking within the context of the current, restricted indication.

Key Studies & References

  1. Tegaserod (ZELNORM) DailyMed Prescribing Information

Frequently Asked Questions (FAQ)

Common questions about Zelmac (FAQ)

Q: How quickly should I expect to feel the constipation relief after starting Zelmac?

A: Clinical studies indicate that patients often reported achieving symptomatic relief from constipation within the first month of starting treatment. This timeline is based on the data used to support the medication’s regulatory approval.

Q: Does the most common side effect, diarrhea, usually go away if I keep taking Zelmac?

A: Official product information suggests that when diarrhea occurs, it is typically transient (short-lasting). In clinical studies, diarrhea was generally reported to have resolved despite continued therapy.

Q: What are the signs of severe diarrhea or volume depletion that should be watched out for?

A: Regulatory warnings highlight that severe diarrhea can lead to serious conditions like hypovolemia (low blood volume), hypotension (low blood pressure), and syncope (fainting). Regulatory documents state that if severe diarrhea, hypotension, or syncope occurs, the drug should be discontinued immediately.

Q: Can Zelmac cause dizziness or lightheadedness when standing up too quickly?

A: Dizziness is listed as a common adverse reaction in regulatory documents. Furthermore, the serious consequence of severe diarrhea can lead to hypotension (low blood pressure), which is a cause of lightheadedness or syncope when changing position.

Q: How is Zelmac different from regular over-the-counter laxatives?

A: According to official information, Zelmac is a selective serotonin-4 (5-HT4) receptor agonist. This means it works by activating specific nerve receptors in the gut to promote movement, which is a targeted action different from the more general mechanisms of most over-the-counter laxatives.

Q: Does Zelmac help with the bloating and gas associated with IBS?

A: Clinical trial summaries indicate that a significantly higher number of patients receiving Zelmac, compared to placebo, reported improvement in both bloating and abdominal pain/discomfort during the first four weeks of the study.

Q: What does it mean that Zelmac is a '5-HT4 receptor partial agonist' in simple terms?

A: This technical term describes how the drug works. It means the active ingredient stimulates the 5-HT4 receptors on nerve cells in the gut. This stimulation triggers a chemical release that helps accelerate the gut’s movement and aid transit.

Q: Is it normal to experience a headache in the first few days of taking Zelmac?

A: Official adverse reaction reports list headache as the most common adverse reaction reported in clinical studies. While its overall incidence is documented, the product information does not specify if the symptom occurs more frequently during the initial days of treatment.

Q: Can Zelmac affect the absorption of other oral medications or supplements?

A: Zelmac is listed as a substrate of the P-glycoprotein (Pgp) transporter, which helps move substances in and out of cells. The drug's activity suggests a potential for interaction with other substances that utilize this transporter, which could potentially change their absorption.

Q: Can Zelmac cause new or worsening abdominal pain, different from the IBS symptoms?

A: Yes, abdominal pain is listed as a common side effect. Furthermore, regulatory warnings state that the medication should be discontinued immediately if an individual experiences any new or sudden worsening of abdominal pain, with or without rectal bleeding.

Q: Is it true that Zelmac was temporarily taken off the market, and if so, why was it brought back?

A: The drug was voluntarily withdrawn in 2007 due to safety concerns regarding a potential increased risk of cardiovascular ischemic events (like heart attack or stroke). It was brought back in 2019 following a complete FDA safety review, resulting in a narrower indication for a specific patient population.

Q: Does Zelmac work by reducing visceral sensitivity in the gut?

A: Official regulatory documents and the mechanism of action indicate that Zelmac does cause the inhibition of visceral sensitivity or 'down-modulation of afferent visceral input' in the gut. This relates to the drug's influence on pain-signaling pathways.

Q: Does Zelmac help with symptoms like straining during bowel movements?

A: Clinical trials conducted for the drug’s approval tracked the symptom of straining with a bowel movement as one of the key characteristics of constipation in IBS-C patients that showed improvement.

Q: Is Zelmac considered a first-line treatment for IBS-C?

A: While the regulatory label doesn't explicitly use the term 'first-line,' the drug's indication is often limited to adult women who have had an inadequate response to other initial therapies, such as dietary changes or osmotic laxatives, before treatment initiation.

Q: Does Zelmac cause fatigue or unusual tiredness?

A: Yes, official regulatory documents list both fatigue and asthenia (meaning a lack or loss of physical strength) as adverse reactions that were reported during clinical trial summaries.

Q: Is the main metabolite of Zelmac (5-methoxyindole-3-carboxylic acid glucuronide) active or inactive?

A: The official clinical pharmacology section clarifies that the major metabolite is inactive. It does not have promotile activity and is devoid of activity at the 5-HT4 receptor.

Q: Can Zelmac lead to increased appetite as a side effect?

A: Yes, increased appetite has been reported as an adverse reaction in the clinical trial summaries detailed in the official product information.

Q: How does Zelmac help with abdominal discomfort and pain, not just constipation?

A: Its mechanism is dual: it stimulates the physical movement of the bowel and also inhibits visceral sensitivity (the pain signals) in the gut. Clinical trials confirmed an improvement in patient-reported abdominal pain and discomfort.

Q: Are there different dosages of Zelmac used for different severities of IBS-C?

A: According to the official Dosage and Administration section, the recommended dosage is a fixed 6 mg twice daily dose. No different dosages are approved for varying severities of Irritable Bowel Syndrome with Constipation (IBS-C).

Q: Could Zelmac affect the ability to drive or operate machinery?

A: Regulatory documents in regions outside of the U.S. that cover 'Effects on ability to drive and use machines' state that no negative effects have been observed on the ability to drive or use machines.

Q: If I have mild diarrhea from Zelmac, should I stop taking it right away?

A: The FDA label does not provide specific guidance for mild diarrhea, but the label includes a warning against initiating the drug in patients who frequently experience or are currently experiencing diarrhea. For severe diarrhea, regulatory warnings state immediate discontinuation is required.

How should Zelmac be stored and disposed of?

How to Store and Dispose of ZELMAC (Tegaserod)

The official labeling defines specific conditions to maintain the stability and safety of ZELMAC tablets.

Storage Requirements

Condition Requirement
Temperature Store at room temperature (controlled).
Protection Must be kept away from heat, moisture, and direct light.
Handling Keep from freezing and store in the original, closed container.
Child Safety Must be stored out of the reach of children.

Disposal Instructions

Unused or expired ZELMAC must be disposed of according to official regulatory guidance. This usually involves following the FDA's protocol for non-flush list drugs: mixing the medicine with an unappealing substance, sealing it in a bag, and discarding it in the household trash. Patients should consult a healthcare professional for specific disposal advice.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zelmac found in:

A-Z Index: